{"id":"W2585127179","doi":"10.1182/blood.v116.21.961.961","title":"Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; CD30; Tolerability; Internal medicine; Oncology; Antibody-drug conjugate; Lymphoma; Gastroenterology; Adverse effect; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004827559,0.0003991414,0.000955026,0.0002414479,0.0002363638,0.0002354142,0.00025631,0.000332199,0.0007939023],"category_scores_gemma":[0.0005490488,0.0001815558,0.000341163,0.0002156116,0.0002519425,0.0002306861,0.0001885661,0.0004643447,0.0002220583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000337776,"about_ca_system_score_gemma":0.0003020001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004273908,"about_ca_topic_score_gemma":0.0009068111,"domain_scores_codex":[0.9998176,0.00005932439,0.00001705999,0.0000383732,0.0000281633,0.0000396197],"domain_scores_gemma":[0.9996979,0.00007142542,0.0000635863,0.0000308872,0.00001400518,0.0001220328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1307824,0.007364483,0.368894,0.00114741,0.001378606,0.008039599,0.001186669,0.004555832,0.1545417,0.0001924908,0.003682862,0.3182339],"study_design_scores_gemma":[0.02868043,0.1819077,0.7551321,0.0000785571,0.0008984718,0.01208321,0.0002002885,0.003497419,0.0108164,0.0001523908,0.006507028,0.00004604483],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978954,0.001273765,0.0001410559,0.00003938192,0.00000847825,0.00005825513,0.00008567524,0.00002821597,0.0004697258],"genre_scores_gemma":[0.9991115,0.0002931811,0.0001310507,0.0000712062,0.00002127423,0.00003501619,0.0001972827,0.00000285509,0.000136614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.000955026,"threshold_uncertainty_score":0.002655864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006542142577756579,"score_gpt":0.2074287419765559,"score_spread":0.2008865993987994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}